| Project/Area Number |
19689018
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (A)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Tohoku University (2008-2009)
Kyoto University (2007) |
|---|
Principal Investigator |
YASUDA Hiroyasu Tohoku University, 未来医工学治療開発センター, 准教授 (90396482)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YANAGIHARA Kazuhiro 京都大学, 大学院・医学系研究科, 准教授 (70332731)
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥26,910,000 (Direct Cost: ¥20,700,000、Indirect Cost: ¥6,210,000)
Fiscal Year 2009: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
Fiscal Year 2008: ¥8,060,000 (Direct Cost: ¥6,200,000、Indirect Cost: ¥1,860,000)
Fiscal Year 2007: ¥11,830,000 (Direct Cost: ¥9,100,000、Indirect Cost: ¥2,730,000)
|
|---|
| Keywords | 非小細胞肺癌 / 低酸素誘導性抗がん薬耐性化機序 / 低酸素誘導因子 / 腫瘍内微小循環 / 一酸化窒素 / ニトログリセリン / 多施設第II相proof of concept臨床試験 / P糖蛋白 / 血管内皮成長因子 / 生存シグナル / 化学療法 / 多施設無作為化臨床試験 / 腫瘍内低酸素 / 腫瘍微小循環 / 腫瘍循環 / P糖蛋白質 |
|---|
| Research Abstract |
In basic science, I showed that nitroglycerin (GTN) significantly reduced HIF-1 alpha, P-glycoprotein, VEGF, P-Akt, and P-CREB in tumor tissues in vivo, resulting in enhancing chemosensitivity of cancer cells to anti-cancer drugs including cisplatin and docetaxel. I started and have been performing three clinical trials regarding combinational chemotherapy with GTN for the next phase III trials, as following : 1) Randomized multicenter phase II trial comparing paclitaxel and carboplatin with GTN with paclitaxel and carboplatin alone in patients with previously untreated advanced non-small cell lung cancer (NSCLC) ; 2) Single arm phase II trial of amrubicin and GTN in patients with previously treated advanced NSCLC as third regimen ; 3) Single arm phase II trial of docetaxel and GTN in elderly patients with previously untreated advanced NSCLC.
|
